First preclinical trial completed in chronic Th2 inflammation model

Welnx Therapeutics completed its first preclinical trial in an animal model of chronic Th2 inflammation in May 2025.

The study established the company's initial proof of concept for locally delivered small molecules in a chronic type 2 inflammatory setting, and provided the foundation for the second preclinical study initiated in July 2026.